International Journal of Bioinformatics and Computational Biology

Editors Overview

ijbcb maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.

Open Access
Special Issue

Biomarker’s role in Cancer Detection

Abstract Submission Deadline : November 30, 2023

Manuscript Submission Deadline : December 25, 2023

Special Issue Description

Biomarkers give a strong and dynamic way to deal with understanding the range of malignancies with applications in observational and scientific studies of disease transmission, randomized, clinical trials, screening, diagnosis, and forecast. In cancer examination and location, a biomarker alludes to a substance or cycle that is indicative of the presence of disease in the body. It may very well be either a particle secreted by malignancy itself or a particular reaction of the body to the presence of cancer. Biomarkers can be estimated in natural media like tissues, cells, or liquids. Cancer biomarkers have changed our way to deal with patient considerations in numerous malignant growth types. The dogma concerning malignant growth markers has been that without a trace of powerful therapies, the best way to deal with the disease was the early diagnosis, trailed by surgical intervention before the cancer had spread. Although a couple of viable methods, for example, DRE for prostate disease, needle biopsy, and mammography for bosom malignant growth have been effectively utilized in the early determination of disease, scarcely any new symptomatic markers have arisen. They have significant expected benefits for patients, especially in adding to “customized” medication, and further developed biomarkers ought to at last prompt enhancements in results and more productive, safe, financially savvy, and proof-based utilization of well-being assets. More explicitly as far as clinical utility, a malignant growth biomarker may gauge the risk of developing the disease in a particular tissue or, on the other hand, may quantify the hazard of malignant growth movement or expected reaction to treatment. Other than giving helpful data in directing clinical navigation, malignant growth biomarkers are progressively connected to explicit subatomic pathway liberations as well as disease pathogenesis to legitimize the use of specific remedial/interventional systems. The reasonable system of disease biomarker advancement has additionally been developing with the quick extension of our omics investigation capacity of clinical biospecimens because of the conventional way of biomarker deployment. In any case, the improvement of many – omic advancements, like genomics and proteomics, has permitted us to monitor enormous numbers of key cellular pathways. This has empowered the distinguishing proof of biomarkers and signaling molecules related to cell development, cell death, and cell metabolism. These regions additionally work in checking the functional disturbance, molecular and cellular damage, and damage response.


Biomarkers , Malignancies , Cancer , Dogma , Clinical

Manuscript Submission information

Manuscripts should be submitted online via the manuscript Engine. Once you register on APID, click here to go to the submission form. Manuscripts can be submitted until the deadline.
All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the email address:[email protected] for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a Double-blind peer-review process. A guide for authors and other relevant information for the submission of manuscripts is available on the Instructions for Authors page.

Participating journals: